A compassionate use study of leriglitazone for treatment of progressive cerebral adrenoleukodystrophy (cALD) in adult male patients

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 17 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Jun 2024 New trial record
11 Jun 2024 According to a Minoryx Therapeutics Media Release, this compassionate-use study was led by Fanny Mochel, MD, Ph.D., professor at the Hospital Universitaire La Pitie-Salpetriere (Paris, France), as part of an early-access program through the French national drug agency (ANSM) that allows for the use of innovative treatments with favorable safety profiles under a Compassionate Access Authorization protocol (ATU).
11 Jun 2024 According to a Minoryx Therapeutics Media Release, resuls from this trial published in the peer-reviewed journal Brain.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com